Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23. (Q38633258)

5 September 2017

Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23. (English)

1 reference

5 September 2017

Chiara Degirolamo

1

1 reference

PubMed ID

26567701

5 September 2017

Carlo Sabbà

series ordinal

2

1 reference

PubMed ID

26567701

5 September 2017

Antonio Moschetta

series ordinal

3

1 reference

5 September 2017

16 November 2015

1 reference

Nature Reviews Drug Discovery

5 September 2017

1 reference

5 September 2017

15

1 reference

5 September 2017

1

1 reference

5 September 2017

51-69

1 reference

https://scigraph.springernature.com/pub.10.1038/nrd.2015.9

5 September 2017

0 references

cites work

The FGF family: biology, pathophysiology and therapy

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Evolution of the Fgf and Fgfr gene families

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Functional evolutionary history of the mouse Fgf gene family

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Receptor specificity of the fibroblast growth factor family

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

FGFs, heparan sulfate and FGFRs: complex interactions essential for development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Structural basis for fibroblast growth factor receptor activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Hormone-like (endocrine) Fgfs: their evolutionary history and roles in development, metabolism, and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Regulation of fibroblast growth factor-23 signaling by klotho

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

BetaKlotho is required for metabolic activity of fibroblast growth factor 21

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Klotho converts canonical FGF receptor into a specific receptor for FGF23

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Co-receptor requirements for fibroblast growth factor-19 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

βKlotho is required for fibroblast growth factor 21 effects on growth and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

FGF-21/FGF-21 receptor interaction and activation is determined by betaKlotho

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Liver-specific activities of FGF19 require Klotho beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

FGF21 requires βklotho to act in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Differential specificity of endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in complex with KLB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Identification of a hormonal basis for gallbladder filling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7alpha-hydroxylase gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

FGF15/19 regulates hepatic glucose metabolism by inhibiting the CREB-PGC-1α pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models--association with liver and adipose tissue effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

FGF-21 as a novel metabolic regulator

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Fibroblast growth factor 21 corrects obesity in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Fibroblast growth factor-19, a novel factor that inhibits hepatic fatty acid synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

FGF21 induces PGC-1alpha and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

A nontumorigenic variant of FGF19 treats cholestatic liver diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Structure and expression of a novel human FGF, FGF-19, expressed in the fetal brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Identification of a novel FGF, FGF-21, preferentially expressed in the liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Research resource: Comprehensive expression atlas of the fibroblast growth factor system in adult mouse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Mouse FGF15 is the ortholog of human and chick FGF19, but is not uniquely required for otic induction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

FGF-19, a novel fibroblast growth factor with unique specificity for FGFR4

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Fibroblast growth factor-21 improves pancreatic beta-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Adipose fibroblast growth factor 21 is up-regulated by peroxisome proliferator-activated receptor gamma and altered metabolic states.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

FGF21 is an Akt-regulated myokine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Regulation of bile acid synthesis under reconstructed enterohepatic circulation in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Involvement of multiple elements in FXR-mediated transcriptional activation of FGF19.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Regulation of bile acid synthesis by fat-soluble vitamins A and D.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

A chronic high-cholesterol diet paradoxically suppresses hepatic CYP7A1 expression in FVB/NJ mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

SREBP-2 negatively regulates FXR-dependent transcription of FGF19 in human intestinal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Lithocholic acid induction of the FGF19 promoter in intestinal cells is mediated by PXR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

FGF19 (fibroblast growth factor 19) as a novel target gene for activating transcription factor 4 in response to endoplasmic reticulum stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Diet1 functions in the FGF15/19 enterohepatic signaling axis to modulate bile acid and lipid levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Selective activation of FGFR4 by an FGF19 variant does not improve glucose metabolism in ob/ob mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Mechanism of tissue-specific farnesoid X receptor in suppressing the expression of genes in bile-acid synthesis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Cytoplasmic tyrosine phosphatase Shp2 coordinates hepatic regulation of bile acid and FGF15/19 signaling to repress bile acid synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Hepatocyte FRS2α is essential for the endocrine fibroblast growth factor to limit the amplitude of bile acid production induced by prandial activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Elevated cholesterol metabolism and bile acid synthesis in mice lacking membrane tyrosine kinase receptor FGFR4

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Impaired negative feedback suppression of bile acid synthesis in mice lacking betaKlotho

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Relevant use of Klotho in FGF19 subfamily signaling system in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Independent repression of bile acid synthesis and activation of c-Jun N-terminal kinase (JNK) by activated hepatocyte fibroblast growth factor receptor 4 (FGFR4) and bile acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Nuclear receptors HNF4α and LRH-1 cooperate in regulating Cyp7a1 in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

CPF: an orphan nuclear receptor that regulates liver-specific expression of the human cholesterol 7alpha-hydroxylase gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Bile acid signaling pathways increase stability of Small Heterodimer Partner (SHP) by inhibiting ubiquitin-proteasomal degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Liver receptor homolog-1 regulates bile acid homeostasis but is not essential for feedback regulation of bile acid synthesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Endocrine fibroblast growth factors 15/19 and 21: from feast to famine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

FGF19 regulates cell proliferation, glucose and bile acid metabolism via FGFR4-dependent and independent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Peripheral reduction of FGFR4 with antisense oligonucleotides increases metabolic rate and lowers adiposity in diet-induced obese mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Fibroblast growth factor receptor 4 (FGFR4) deficiency improves insulin resistance and glucose metabolism under diet-induced obesity conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Central action of FGF19 reduces hypothalamic AGRP/NPY neuron activity and improves glucose metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Fibroblast growth factor-19 action in the brain reduces food intake and body weight and improves glucose tolerance in male rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

FGF19 action in the brain induces insulin-independent glucose lowering

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Detection of FGF15 in plasma by stable isotope standards and capture by anti-peptide antibodies and targeted mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

High expression of the bile salt-homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Fibroblast growth factor 19 serum levels: relation to renal function and metabolic parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Bile acid malabsorption in inflammatory bowel disease: assessment by serum markers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

A new mechanism for bile acid diarrhea: defective feedback inhibition of bile acid biosynthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

The hepatic response to FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Separating mitogenic and metabolic activities of fibroblast growth factor 19 (FGF19).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Expression of fibroblast growth factor 19 is associated with recurrence and poor prognosis of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Regulation of amphiregulin gene expression by β-catenin signaling in human hepatocellular carcinoma cells: a novel crosstalk between FGF19 and the EGFR system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Ileal FGF15 contributes to fibrosis-associated hepatocellular carcinoma development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Inhibition of fibroblast growth factor 19 reduces tumor growth by modulating beta-catenin signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Antibody-mediated inhibition of fibroblast growth factor 19 results in increased bile acids synthesis and ileal malabsorption of bile acids in cynomolgus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

C-terminal tail of FGF19 determines its specificity toward Klotho co-receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Separating Tumorigenicity from Bile Acid Regulatory Activity for Endocrine Hormone FGF19.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

PPARalpha is a key regulator of hepatic FGF21.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Glucocorticoids regulate the metabolic hormone FGF21 in a feed-forward loop.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Activation of the farnesoid X receptor induces hepatic expression and secretion of fibroblast growth factor 21

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Retinoic acid receptor β stimulates hepatic induction of fibroblast growth factor 21 to promote fatty acid oxidation and control whole-body energy homeostasis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Thyroid hormone regulates hepatic expression of fibroblast growth factor 21 in a PPARalpha-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Thiazolidinediones are potent inducers of fibroblast growth factor 21 expression in the liver.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Sodium butyrate stimulates expression of fibroblast growth factor 21 in liver by inhibition of histone deacetylase 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Metformin stimulates FGF21 expression in primary hepatocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Time-imposed daily restricted feeding induces rhythmic expression of Fgf21 in white adipose tissue of mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Fibroblast growth factor-21 regulates PPARγ activity and the antidiabetic actions of thiazolidinediones.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Identification of a domain within peroxisome proliferator-activated receptor gamma regulating expression of a group of genes containing fibroblast growth factor 21 that are selectively repressed by SIRT1 in adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Thermogenic activation induces FGF21 expression and release in brown adipose tissue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

FGF21 regulates PGC-1α and browning of white adipose tissues in adaptive thermogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Skeletal muscle mitochondrial uncoupling drives endocrine cross-talk through the induction of FGF21 as a myokine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

The breadth of FGF21's metabolic actions are governed by FGFR1 in adipose tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Treating diabetes and obesity with an FGF21-mimetic antibody activating the βKlotho/FGFR1c receptor complex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

An FGF21-adiponectin-ceramide axis controls energy expenditure and insulin action in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

A critical role for the peroxisome proliferator-activated receptor alpha (PPARalpha) in the cellular fasting response: the PPARalpha-null mouse as a model of fatty acid oxidation disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Circulating FGF21 is liver derived and enhances glucose uptake during refeeding and overfeeding.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Fibroblast growth factor 21 controls glycemia via regulation of hepatic glucose flux and insulin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Interplay between FGF21 and insulin action in the liver regulates metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

FGF21 regulates metabolism and circadian behavior by acting on the nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

FGF21 maintains glucose homeostasis by mediating the cross talk between liver and brain during prolonged fasting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Diabetes mellitus and genetically programmed defects in beta-cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

High glucose represses β-klotho expression and impairs fibroblast growth factor 21 action in mouse pancreatic islets: involvement of peroxisome proliferator-activated receptor γ signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Loss of fibroblast growth factor 21 action induces insulin resistance, pancreatic islet hyperplasia and dysfunction in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Fibroblast growth factor 21 reduces the severity of cerulein-induced pancreatitis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Inhibition of growth hormone signaling by the fasting-induced hormone FGF21.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Fibroblast growth factor 21, the endocrine FGF pathway and novel treatments for metabolic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

The starvation hormone, fibroblast growth factor-21, extends lifespan in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

FGF21 mediates the lipid metabolism response to amino acid starvation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

FGF21 is an endocrine signal of protein restriction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

PPARγ signaling and metabolism: the good, the bad and the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Fibroblast growth factor 21 is not required for the antidiabetic actions of the thiazoladinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor γ.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Pharmacologic Effects of FGF21 Are Independent of the "Browning" of White Adipose Tissue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Discrete Aspects of FGF21 In Vivo Pharmacology Do Not Require UCP1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

The sum of all browning in FGF21 therapeutics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Tissue-specific actions of the metabolic hormones FGF15/19 and FGF21.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Fibroblast growth factor 21 action in the brain increases energy expenditure and insulin sensitivity in obese rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

FGF21 contributes to neuroendocrine control of female reproduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

FGF21 acts centrally to induce sympathetic nerve activity, energy expenditure, and weight loss.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

FGF21 deletion exacerbates diabetic cardiomyopathy by aggravating cardiac lipid accumulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Fibroblast growth factor 21 protects against cardiac hypertrophy in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Fibroblast growth factor 21 protects the heart from oxidative stress.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Endocrine protection of ischemic myocardium by FGF21 from the liver and adipose tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARalpha activation in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Circadian expression of FGF21 is induced by PPARalpha activation in the mouse liver.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Plasma FGF21 displays a circadian rhythm during a 72-h fast in healthy female volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Circadian rhythm of circulating fibroblast growth factor 21 is related to diurnal changes in fatty acids in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Various oscillation patterns of serum fibroblast growth factor 21 concentrations in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Circulating fibroblast growth factor 21 is induced by peroxisome proliferator-activated receptor agonists but not ketosis in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Fibroblast growth factor-21 is expressed in neonatal and pheochromocytoma-induced adult human brown adipose tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Irisin and FGF21 are cold-induced endocrine activators of brown fat function in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Serum levels of FGF-21 are increased in coronary heart disease patients and are independently associated with adverse lipid profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Plasma concentrations of fibroblast growth factors 19 and 21 in patients with anorexia nervosa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Inventing new medicines: The FGF21 story

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Fibroblast growth factor 21 as an emerging metabolic regulator: clinical perspectives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

LY2405319, an Engineered FGF21 Variant, Improves the Metabolic Status of Diabetic Monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Long-acting FGF21 has enhanced efficacy in diet-induced obese mice and in obese rhesus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Increased fibroblast growth factor 21 expression in high-fat diet-sensitive non-human primates (Macaca mulatta).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Obesity is a fibroblast growth factor 21 (FGF21)-resistant state

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

FGF21-based pharmacotherapy--potential utility for metabolic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Rationale-Based Engineering of a Potent Long-Acting FGF21 Analog for the Treatment of Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Rational design of a fibroblast growth factor 21-based clinical candidate, LY2405319

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

FGF21 analogs of sustained action enabled by orthogonal biosynthesis demonstrate enhanced antidiabetic pharmacology in rodents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Polyethylene glycol modified FGF21 engineered to maximize potency and minimize vacuole formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

A better anti-diabetic recombinant human fibroblast growth factor 21 (rhFGF21) modified with polyethylene glycol

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Pegylated Fgf21 rapidly normalizes insulin-stimulated glucose utilization in diet-induced insulin resistant mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

A solid-phase PEGylation strategy for protein therapeutics using a potent FGF21 analog

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Development of a novel long-acting antidiabetic FGF21 mimetic by targeted conjugation to a scaffold antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Pharmacokinetics (PK), pharmacodynamics (PD) and integrated PK/PD modeling of a novel long acting FGF21 clinical candidate PF-05231023 in diet-induced obese and leptin-deficient obese mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Mechanistic investigation of the preclinical pharmacokinetics and interspecies scaling of PF-05231023, a fibroblast growth factor 21-antibody protein conjugate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Chemical generation of bispecific antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

FGF21 can be mimicked in vitro and in vivo by a novel anti-FGFR1c/β-Klotho bispecific protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

1alpha,25-Dihydroxyvitamin D3 upregulates FGF23 gene expression in bone: the final link in a renal-gastrointestinal-skeletal axis that controls phosphate transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Genetic dissection of phosphate- and vitamin D-mediated regulation of circulating Fgf23 concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Parathyroid hormone activates the orphan nuclear receptor Nurr1 to induce FGF23 transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Molecular interactions of FGF23 and PTH in phosphate regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Fibroblast growth factor 23 acts on the parathyroid to decrease parathyroid hormone secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Leptin stimulates fibroblast growth factor 23 expression in bone and suppresses renal 1alpha,25-dihydroxyvitamin D3 synthesis in leptin-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

The role of vitamin D in the FGF23, klotho, and phosphate bone-kidney endocrine axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Mutation of the mouse klotho gene leads to a syndrome resembling ageing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Recent advances in renal phosphate handling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Klotho: a novel phosphaturic substance acting as an autocrine enzyme in the renal proximal tubule

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

FGF23 acts directly on renal proximal tubules to induce phosphaturia through activation of the ERK1/2-SGK1 signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Hypervitaminosis D and premature aging: lessons learned from Fgf23 and Klotho mutant mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Ablation of vitamin D signaling rescues bone, mineral, and glucose homeostasis in Fgf-23 deficient mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Reversal of mineral ion homeostasis and soft-tissue calcification of klotho knockout mice by deletion of vitamin D 1alpha-hydroxylase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

1,25-Dihydroxyvitamin D3/VDR-mediated induction of FGF23 as well as transcriptional control of other bone anabolic and catabolic genes that orchestrate the regulation of phosphate and calcium mineral metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Parathyroid cell resistance to fibroblast growth factor 23 in secondary hyperparathyroidism of chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Increased parathyroid expression of klotho in uremic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

FGF23 induces left ventricular hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

FGF23 is a novel regulator of intracellular calcium and cardiac contractility in addition to cardiac hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

FGF23 concentrations vary with disease status in autosomal dominant hypophosphatemic rickets.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Relationship between circulating FGF23 and total body atherosclerosis in the community

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Skeletal secretion of FGF-23 regulates phosphate and vitamin D metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Targeted deletion of Klotho in kidney distal tubule disrupts mineral metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

The bone and beyond: 'Dem bones' are made for more than walking.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Anti-FGF23 neutralizing antibodies show the physiological role and structural features of FGF23.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Therapeutic effects of anti-FGF23 antibodies in hypophosphatemic rickets/osteomalacia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Treatment of established left ventricular hypertrophy with fibroblast growth factor receptor blockade in an animal model of CKD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Antibody-mediated activation of FGFR1 induces FGF23 production and hypophosphatemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Prevention of spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice by intestinal-specific farnesoid X receptor reactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Selective Activation of Nuclear Bile Acid Receptor FXR in the Intestine Protects Mice Against Cholestasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Klotho spins the thread of life--what does Klotho do to the receptors of fibroblast growth factor-23 (FGF23)?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Lanthanum carbonate reduces FGF23 in chronic kidney disease Stage 3 patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

Restoration of leptin responsiveness in diet-induced obese mice using an optimized leptin analog in combination with exendin-4 or FGF21

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2015.9

HNF4 and COUP-TFII interact to modulate transcription of the cholesterol 7alpha-hydroxylase gene (CYP7A1).

31 March 2020

1 reference

12 December 2020

The parathyroid is a target organ for FGF23 in rats

1 reference

12 December 2020

Amelioration of type 2 diabetes by antibody-mediated activation of fibroblast growth factor receptor 1.

1 reference

12 December 2020

FGF21: a novel prospect for the treatment of metabolic diseases.

1 reference

12 December 2020

Stressed Liver and Muscle Call on Adipocytes with FGF21

1 reference

12 December 2020

Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism

1 reference

12 December 2020

A novel fibroblast growth factor gene expressed in the developing nervous system is a downstream target of the chimeric homeodomain oncoprotein E2A-Pbx1.

1 reference

12 December 2020

Evolutionary conservation of CCND1-ORAOV1-FGF19-FGF4 locus from zebrafish to human.

1 reference

12 December 2020

Serum concentrations of fibroblast growth factor 19 in patients with obesity and type 2 diabetes mellitus: the influence of acute hyperinsulinemia, very-low calorie diet and PPAR-α agonist treatment.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRD.2015.9

1 reference

5 September 2017

1 reference

PubMed ID

26567701